# US 2011/0224275 A1 · Inhibitors of matrix metalloproteinases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0224275 A1
- Document ID: US20110224275A1
- Status: Published application
- Kind: A1
- Application number: 13/047,605
- Filed: 2011-03-14
- Published: 2011-09-15
- Earliest claimed: 2005-05-19
- Assignees: Notre Dame University; Wayne State University
- Inventors: Mijoon Lee; Masahiro Ikejiri; Mayland Chang; Rafael Fridman; Shahriar Mobashery
- Web page: https://patentgrep.com/patent/US20110224275A1

## CPC

- C07D 303/34: with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 331/02: Three-membered rings
- C07D 407/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07F 9/564: Three-membered rings
- C07F 9/65505: {Phosphonic acids containing oxirane groups; esters thereof}
- C07F 9/655309: {the sulfur atom being part of a three-membered ring}
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.

## Claims

### Claim 1

(canceled)

### Claim 2

A compound of Formula (30):
wherein
R3 and R4 are each independently H, OH, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkanoyl, (C1-C6)alkanoyloxy, aryl, heteroaryl, carboxy, cyano, nitro, halo, trifluoromethyl, trifluoromethoxy, SR5, SO2N(R5)2, NR5R5, or COOR5;
each R5 is independently H, (C1-C6)alkyl, (C1-C6)alkanoyl, (C6-C10)aroyl, aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, or a nitrogen protecting group;
any alkyl, amino, aryl, or heteroaryl is optionally substituted with 1 to about 5 (C1-C6)alkyl, (C1-C6)alkoxy, aryl, heteroaryl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, nitro, halo, amino, or hydroxy groups;
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2 wherein R3 is H.

### Claim 4 (depends on 2)

The compound of claim 2 wherein R4 is H.

### Claim 5 (depends on 2)

The compound of claim 2 wherein both R3 and R4 are H.

### Claim 6 (depends on 2)

The compound of claim 2 wherein the position of the —NH2 of Formula (30) is ortho or para to the oxygen linking the two aryl rings in Formula (30).

### Claim 7 (depends on 2)

The compound of claim 2 wherein the position of the —NH2 of Formula (30) is ortho or meta to the oxygen linking the two aryl rings in Formula (30).

### Claim 8 (depends on 5)

The compound of claim 5 wherein the position of the —NH2 of Formula (30) is ortho or para to the oxygen linking the two aryl rings in Formula (30).

### Claim 9 (depends on 5)

The compound of claim 5 wherein the position of the —NH2 of Formula (30) is ortho or meta to the oxygen linking the two aryl rings in Formula (30).

### Claim 10 (depends on 2)

The compound of claim 2 wherein the compound is in the form of a pharmaceutically acceptable salt.

### Claim 11 (depends on 5)

The compound of claim 5 wherein the compound is in the form of a pharmaceutically acceptable salt.

### Claim 12 (depends on 10)

The pharmaceutically acceptable salt of claim 10 wherein the salt is derived from hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethane disulfonic acid, oxalic acid, or isethionic acid.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

### Claim 14 (depends on 13)

The composition of claim 13 wherein the compound is present at about 0.075% w/w to 20% w/w.

### Claim 15 (depends on 14)

The composition of claim 14 wherein the compound is present at about 0.2% w/w to 15% w/w.

### Claim 16 (depends on 13)

The composition of claim 13 wherein the composition is formulated for injection, oral administration, or topical administration.

### Claim 17 (depends on 16)

The composition of claim 16 wherein the composition is formulated for injection and the composition comprises a buffer.

### Claim 18 (depends on 16)

The composition of claim 16 wherein the composition is formulated for injection and the composition is an isotonic sterile injectable preparation.

### Claim 19 (depends on 16)

The composition of claim 16 wherein the composition is formulated for injection and the composition has a pH of about 7 to 10.

### Claim 20 (depends on 16)

The composition of claim 16 wherein the composition is formulated for oral administration and the composition is a tablet, troche, capsule, lozenge, emulsion, aqueous or oil suspension, dispersible powder or granule, syrup, or elixir.

### Claim 21 (depends on 16)

The composition of claim 16 wherein the composition is formulated for topical administration and composition is an ointment or cream.
